Please enable JavaScript to continue using this application.

Compare $PBLS vs $VKTX | Chartloom

Compare

$PBLS vs $VKTX

Parabilis Medicines Inc · Viking Therapeutics Inc

PBLS

Parabilis Medicines Inc

VKTX

Viking Therapeutics Inc

Compare $PBLS vs $VKTX

Comparing Parabilis Medicines Inc and Viking Therapeutics Inc

PBLSParabilis Medicines Inc

VKTXViking Therapeutics Inc

PBLSParabilis Medicines Inc

Market cap

$3.20B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

581.53x

Rev growth (TTM)

—

YTD performance

-13.0%

52W performance

-13.0%

FCF yield

-1.7%

VKTXViking Therapeutics Inc

Market cap

$3.33B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-19.5%

52W performance

-11.9%

FCF yield

-12.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PBLS

VKTX

Detailed metrics comparison

PBLS

Parabilis Medicines Inc

VKTX

Viking Therapeutics Inc

Market Cap

PBLS$3.20B

VKTX$3.33B

Enterprise Value

PBLS$2.12B

VKTX$3.20B

Price

PBLS$27.48

VKTX$28.51

P/E Ratio

PBLSN/A

VKTXN/A

P/S Ratio

PBLS21,642.36x

VKTX0.00x

EV/Sales

PBLS14,348.08x

VKTX0.00x

EV/EBITDA

PBLS0.00x

VKTX0.00x

P/B Ratio

PBLS3.57x

VKTX9.38x

P/FCF Ratio

PBLSN/A

VKTXN/A

EV/FCF

PBLS-39.47x

VKTX-7.65x

PEG Ratio

PBLSN/A

VKTXN/A

Forward P/E (NTM)

PBLSN/A

VKTXN/A

Forward P/S (NTM)

PBLS581.53x

VKTXN/A

Revenue (TTM)

PBLS$148K

VKTX$0

Revenue Growth (YoY)

PBLSN/A

VKTXN/A

Forward Rev Growth

PBLS212.5%

VKTX236.5%

Gross Margin (TTM)

PBLS0.0%

VKTX0.0%

Operating Margin (TTM)

PBLS0.0%

VKTX0.0%

EBITDA Margin (TTM)

PBLS-65635.1%

VKTX0.0%

Net Margin (TTM)

PBLS-93131.8%

VKTX0.0%

FCF Margin (TTM)

PBLS-36356.1%

VKTXN/A

Net Income (TTM)

PBLS$-138M

VKTX$-535M

FCF (TTM)

PBLS$-54M

VKTX$-418M

EPS (TTM)

PBLS-$1.12

VKTX-$4.60

ROE (TTM)

PBLS0.0%

VKTX-9456.0%

ROA (TTM)

PBLS0.0%

VKTX-8274.0%

ROIC (TTM)

PBLS0.0%

VKTX-9456.0%

Cash

PBLS$1.09B

VKTX$126M

Debt

PBLS$8M

VKTX$0

Net Cash/Debt

PBLS$1.08B

VKTX$126M

Current Ratio (TTM)

PBLS17.91x

VKTX4.72x

Quick Ratio (TTM)

PBLS17.83x

VKTX4.57x

Debt/Equity (TTM)

PBLS0.01x

VKTX0.00x

Debt/Assets (TTM)

PBLS0.0%

VKTX0.0%

Interest Coverage (TTM)

PBLSN/A

VKTXN/A

Net Debt/EBITDA (TTM)

PBLS0.00x

VKTX0.00x

Beta

PBLS-1.08

VKTX0.69

52W Performance

PBLS-13.0%

VKTX-11.9%

YTD Performance

PBLS-13.0%

VKTX-19.5%

% from 52W High

PBLS-35.3%

VKTX-33.9%

% from 52W Low

PBLS12.1%

VKTX10.6%

Asset Turnover (TTM)

PBLS0.00x

VKTX0.00x

FCF Yield (TTM)

PBLS-1.7%

VKTX-12.6%

Earnings Yield (TTM)

PBLS-4.3%

VKTX-16.1%

Dividend Yield (TTM)

PBLSN/A

VKTXN/A

Rule of 40

PBLS-36,356.1

VKTX0.0

EV/GP/RG

PBLSN/A

VKTXN/A

Ticker research

View PBLS research View VKTX research

Metric	PBLS Parabilis Medicines Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.20B	$3.33B
Enterprise Value	$2.12B	$3.20B
Price	$27.48	$28.51
P/E Ratio	N/A	N/A
P/S Ratio	21,642.36x	0.00x
EV/Sales	14,348.08x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.57x	9.38x
P/FCF Ratio	N/A	N/A
EV/FCF	-39.47x	-7.65x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	581.53x	N/A
Revenue & Growth
Revenue (TTM)	$148K	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	212.5%	236.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-65635.1%	0.0%
Net Margin (TTM)	-93131.8%	0.0%
FCF Margin (TTM)	-36356.1%	N/A
Net Income (TTM)	$-138M	$-535M
FCF (TTM)	$-54M	$-418M
EPS (TTM)	-$1.12	-$4.60
ROE (TTM)	0.0%	-9456.0%
ROA (TTM)	0.0%	-8274.0%
ROIC (TTM)	0.0%	-9456.0%
Financial Health
Cash	$1.09B	$126M
Debt	$8M	$0
Net Cash/Debt	$1.08B	$126M
Current Ratio (TTM)	17.91x	4.72x
Quick Ratio (TTM)	17.83x	4.57x
Debt/Equity (TTM)	0.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.08	0.69
52W Performance	-13.0%	-11.9%
YTD Performance	-13.0%	-19.5%
% from 52W High	-35.3%	-33.9%
% from 52W Low	12.1%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-1.7%	-12.6%
Earnings Yield (TTM)	-4.3%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-36,356.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View PBLS research	View VKTX research

Valuation

P/S Ratio

VKTX

0.00x

PBLS

21,642.36x

EV/FCF

PBLS

-39.47x

VKTX

-7.65x

Growth & revenue

Forward Revenue Growth

VKTX

236.5%

PBLS

212.5%

Profitability & performance

Gross Margin

PBLS

0.0%

VKTX

0.0%

ROE

PBLS

0.0%

VKTX

-9456.0%

FCF Yield %

PBLS

-1.7%

VKTX

-12.6%

52-Week Performance

VKTX

-11.9%

PBLS

-13.0%

Detailed metrics comparison

PBLS

Parabilis Medicines Inc

VKTX

Viking Therapeutics Inc

Market Cap

PBLS$3.20B

VKTX$3.33B

Enterprise Value

PBLS$2.12B

VKTX$3.20B

Price

PBLS$27.48

VKTX$28.51

P/E Ratio

PBLSN/A

VKTXN/A

P/S Ratio

PBLS21,642.36x

VKTX0.00x

EV/Sales

PBLS14,348.08x

VKTX0.00x

EV/EBITDA

PBLS0.00x

VKTX0.00x

P/B Ratio

PBLS3.57x

VKTX9.38x

P/FCF Ratio

PBLSN/A

VKTXN/A

EV/FCF

PBLS-39.47x

VKTX-7.65x

PEG Ratio

PBLSN/A

VKTXN/A

Forward P/E (NTM)

PBLSN/A

VKTXN/A

Forward P/S (NTM)

PBLS581.53x

VKTXN/A

Revenue (TTM)

PBLS$148K

VKTX$0

Revenue Growth (YoY)

PBLSN/A

VKTXN/A

Forward Rev Growth

PBLS212.5%

VKTX236.5%

Gross Margin (TTM)

PBLS0.0%

VKTX0.0%

Operating Margin (TTM)

PBLS0.0%

VKTX0.0%

EBITDA Margin (TTM)

PBLS-65635.1%

VKTX0.0%

Net Margin (TTM)

PBLS-93131.8%

VKTX0.0%

FCF Margin (TTM)

PBLS-36356.1%

VKTXN/A

Net Income (TTM)

PBLS$-138M

VKTX$-535M

FCF (TTM)

PBLS$-54M

VKTX$-418M

EPS (TTM)

PBLS-$1.12

VKTX-$4.60

ROE (TTM)

PBLS0.0%

VKTX-9456.0%

ROA (TTM)

PBLS0.0%

VKTX-8274.0%

ROIC (TTM)

PBLS0.0%

VKTX-9456.0%

Cash

PBLS$1.09B

VKTX$126M

Debt

PBLS$8M

VKTX$0

Net Cash/Debt

PBLS$1.08B

VKTX$126M

Current Ratio (TTM)

PBLS17.91x

VKTX4.72x

Quick Ratio (TTM)

PBLS17.83x

VKTX4.57x

Debt/Equity (TTM)

PBLS0.01x

VKTX0.00x

Debt/Assets (TTM)

PBLS0.0%

VKTX0.0%

Interest Coverage (TTM)

PBLSN/A

VKTXN/A

Net Debt/EBITDA (TTM)

PBLS0.00x

VKTX0.00x

Beta

PBLS-1.08

VKTX0.69

52W Performance

PBLS-13.0%

VKTX-11.9%

YTD Performance

PBLS-13.0%

VKTX-19.5%

% from 52W High

PBLS-35.3%

VKTX-33.9%

% from 52W Low

PBLS12.1%

VKTX10.6%

Asset Turnover (TTM)

PBLS0.00x

VKTX0.00x

FCF Yield (TTM)

PBLS-1.7%

VKTX-12.6%

Earnings Yield (TTM)

PBLS-4.3%

VKTX-16.1%

Dividend Yield (TTM)

PBLSN/A

VKTXN/A

Rule of 40

PBLS-36,356.1

VKTX0.0

EV/GP/RG

PBLSN/A

VKTXN/A

Ticker research

View PBLS research View VKTX research

Metric	PBLS Parabilis Medicines Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.20B	$3.33B
Enterprise Value	$2.12B	$3.20B
Price	$27.48	$28.51
P/E Ratio	N/A	N/A
P/S Ratio	21,642.36x	0.00x
EV/Sales	14,348.08x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.57x	9.38x
P/FCF Ratio	N/A	N/A
EV/FCF	-39.47x	-7.65x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	581.53x	N/A
Revenue & Growth
Revenue (TTM)	$148K	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	212.5%	236.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-65635.1%	0.0%
Net Margin (TTM)	-93131.8%	0.0%
FCF Margin (TTM)	-36356.1%	N/A
Net Income (TTM)	$-138M	$-535M
FCF (TTM)	$-54M	$-418M
EPS (TTM)	-$1.12	-$4.60
ROE (TTM)	0.0%	-9456.0%
ROA (TTM)	0.0%	-8274.0%
ROIC (TTM)	0.0%	-9456.0%
Financial Health
Cash	$1.09B	$126M
Debt	$8M	$0
Net Cash/Debt	$1.08B	$126M
Current Ratio (TTM)	17.91x	4.72x
Quick Ratio (TTM)	17.83x	4.57x
Debt/Equity (TTM)	0.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.08	0.69
52W Performance	-13.0%	-11.9%
YTD Performance	-13.0%	-19.5%
% from 52W High	-35.3%	-33.9%
% from 52W Low	12.1%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-1.7%	-12.6%
Earnings Yield (TTM)	-4.3%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-36,356.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View PBLS research	View VKTX research